Artificial pancreas device system market seen reaching $3.92 billion by 2030

The artificial pancreas device system market is projected to expand from $2.06 billion in 2025 to $3.92 billion by 2030, driven by rising diabetes cases, wider use of continuous glucose monitoring and insulin pumps, and stronger demand for automated glucose control. North America held the largest share in 2025, while Asia-Pacific is expected to grow fastest.

Why it matters: - Artificial pancreas device systems automate glucose control for people living with diabetes and can reduce the need for manual blood sugar checks and insulin injections. - The market’s growth points to rising demand for connected diabetes care tools as diabetes prevalence increases worldwide. - The technology is gaining relevance as healthcare systems push for more personalized and remote diabetes management.

What happened: - The artificial pancreas device system market is projected to rise from $2.06 billion in 2025 to $2.35 billion in 2026. - The market is forecast to reach $3.92 billion by 2030. - The forecast implies a 13.9% compound annual growth rate in 2026 and a 13.7% CAGR through 2030. - The Business Research Company released the market outlook on Nov. 3, 2026. - The report includes market attractiveness scoring, total addressable market analysis, company scoring matrices, Excel-based forecasting dashboards, market hotspots infographics, and updated graphics and tables. - The report also covers key technologies and future trend analysis. - A free sample report and the full market report are available online.

The details: - Market growth has been fueled by rising diabetes incidence, broader adoption of insulin pump technology, expanded use of continuous glucose monitoring, improved sensor accuracy, and greater awareness of automated diabetes care. - Forecast-period growth is tied to demand for fully automated glucose regulation. - Investment in digital diabetes care is increasing. - Remote patient monitoring capabilities are expanding. - Personalized insulin therapies are gaining traction. - Regulatory support for advanced diabetes devices is strengthening. - Closed-loop glucose control systems are becoming more common. - These systems combine continuous glucose monitoring with insulin pumps. - Predictive algorithms are improving insulin delivery and helping stabilize glucose levels. - Wearable diabetes management devices are also growing in use. - The artificial pancreas device system connects a continuous glucose monitor with an insulin pump and uses an algorithm to adjust insulin delivery in real time.

Between the lines: - The report links APDS demand to pancreatic cancer prevalence, arguing that more advanced diabetes management tools become more relevant as pancreatic cancer cases rise. - Cancer Australia reported 4,506 new pancreatic cancer cases diagnosed in 2023, up from 3,751 cases over the previous five years. - North America held the largest share of the market in 2025. - Asia-Pacific is expected to post the fastest growth during the forecast period. - The regional analysis also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa.

What's next: - The market is expected to benefit from continued adoption of closed-loop systems and smarter insulin delivery software. - Wider use of wearable devices and patient-centric automation could expand the user base. - Ongoing advances in sensor accuracy and monitoring may support further adoption through 2030. - The Business Research Company is offering direct contact channels for buyers seeking the report or related market materials.

The bottom line: - Artificial pancreas device systems are moving from niche diabetes technology to a faster-growing automated care category, with demand set to stay strong through 2030.